La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Senti Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Senti Biosciences..

Senti Biosciences (NASDAQ:SNTI) Azioni, Catena delle Opzioni

SENTI BIOSCIENCES INC

Senti Biosciences

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Senti Biosciences Inc

News

Health Care

Press Releases

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live

Senti Biosciences Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Earnings

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

General

Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

AKTX

AMIX

CNSP

MBRX

NUWE

NVNO

OTLK

PALI

SNTI

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Annovis Bio

AlphaTON Capital

BioAtla

Boundless Bio

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

Generation Bio

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Kezar Life Sciences

LAVA Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

Lunai Bioworks

Rein Therapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Senti Biosciences

Senti Biosciences (SNTI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO